Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).
Jacob Laubach
Research Funding - Novartis; Onyx
Noopur S. Raje
No relevant relationships to disclose
Philippe Armand
No relevant relationships to disclose
Robert L. Schlossman
No relevant relationships to disclose
Jacalyn Rosenblatt
No relevant relationships to disclose
Jeffrey Matous
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Jacquelyn Ann Hedlund
No relevant relationships to disclose
Michael Gary Martin
No relevant relationships to disclose
Craig H. Reynolds
Consultant or Advisory Role - Celgene; Pfizer; Threshold Pharmaceuticals
Honoraria - Celgene; Pfizer
Kenneth H. Shain
No relevant relationships to disclose
Ira Zackon
Other Remuneration - Millennium
Laura Stampleman
No relevant relationships to disclose
Erica Boswell
No relevant relationships to disclose
Stacey Chuma
No relevant relationships to disclose
Rebecca Liguori
No relevant relationships to disclose
Damian Handisides
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Stew Kroll
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
Kenneth Carl Anderson
Consultant or Advisory Role - Celgene; Gilead Sciences; Millennium; Sanofi
Stock Ownership - Acetylon Pharmaceuticals; OncoPep
Paul G. Richardson
No relevant relationships to disclose
Irene M. Ghobrial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Onyx